Abstract
The long‑term survival rate in paediatric acute lymphoblastic leukaemia (ALL) exceeds 80%; however, the outcome of adult ALL remains to be poor. Glucocorticoids (GCs) are the preferred drugs in the traditional treatment of ALL patients. In the anti‑leukaemia molecular mechanisms of GCs, c‑Myc inhibition serves a critical role. In the present study, a c‑Myc inhibitor that increased the sensitivity to GCs in NALM6 cells of the B‑cell‑ALL cell line and CEM cells of the T‑cell‑ALL cell line was investigated. The data demonstrated that 10058‑F4, a c‑Myc inhibitor, increased the growth inhibition, G0/G1 phase arrest and apoptosis of the NALM6 and CEM cells as induced by dexamethasone (DXM), a type of GC. Additionally, 10058‑F4 reinforced the decreased expressions of c‑Myc, cyclin‑dependent kinase (CDK)‑4 and CDK6 in the NALM6 and CEM cells treated with DXM. These findings indicated that DXM in combination with the c‑Myc inhibitor 10058‑F4 may be a novel, potent therapeutic strategy for the treatment of ALL.
References
Nov 20, 1998·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·N Schreiber-Agus, R A DePinho
Jun 22, 1999·Molecular and Cellular Biology·M K MateyakJ M Sedivy
Jun 23, 1999·Oncogene·B Lüscher, L G Larsson
Sep 29, 1999·Advances in Experimental Medicine and Biology·P S Gaynon, A L Carrel
Feb 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·H HermekingK W Kinzler
Nov 9, 2000·The Journal of Steroid Biochemistry and Molecular Biology·F ZhouE B Thompson
Jan 23, 2002·Cell Death and Differentiation·C W Distelhorst
Jan 17, 2003·Leukemia·W J E TissingR Pieters
Sep 19, 2003·Oncogene·Xiaoying YinEdward V Prochownik
Jul 15, 2004·Blood·Ching-Hon PuiUNKNOWN Total Therapy Study XIIIB at St Jude Children's Research Hospital
Oct 9, 2004·Science·Andrew P WengJon C Aster
Oct 19, 2006·Experimental Hematology·Ming-Jer HuangH Eugene Liu
Jul 25, 2007·The Journal of Experimental Medicine·Jennifer O'NeilA Thomas Look
Dec 1, 2007·Blood·Anthony H GoldstoneJacob M Rowe
May 30, 2008·Cancer Chemotherapy and Pharmacology·Jianxia GuoJulie L Eiseman
Dec 7, 2010·Genes & Cancer·Edward V Prochownik, Peter K Vogt
Apr 20, 2011·Current Drug Targets·Arash S SaffarAbdelilah S Gounni
Sep 24, 2011·Leukemia·T HolienA Sundan
Apr 17, 2012·Molecular Cancer Therapeutics·Jeremy B SamonAdolfo A Ferrando
Aug 21, 2012·Blood·Christopher J OttDavid M Weinstock
Jan 8, 2014·Blood·Justine E RoderickMichelle A Kelliher
Mar 7, 2014·Leukemia & Lymphoma·Yan LiuYi-Ping Zhu
Aug 15, 2014·Oncology Letters·Qitian MuJie Jin
Apr 1, 2015·Molecular Cancer Therapeutics·Deepti SoodguptaMichael H Tomasson
Oct 31, 2015·Oncotarget·Zheng GeChunhua Song
Nov 18, 2015·American Journal of Hematology·Noelle V Frey, David L Porter
May 22, 2016·Blood·Jae H ParkRenier J Brentjens
Jun 10, 2016·Nature·Sheela A AbrahamTessa L Holyoake
Feb 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yana PikmanKimberly Stegmaier